DocCode — SEQ. TXT
`
`SCORE Placeholder Sheet for IFW Content
`
`Application Number: 14845644
`
`Document Date: 09/04/2015
`
`The presence of this form in the IFW record indicates that the following document type was received
`in electronic format on the date identified above. This content is stored in the SCORE database.
`
`Since this was an electronic submission, there is no physical artifact folder, no artifact folder is
`recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW
`record were created from the original documents that are stored in SCORE.
`
`Sequence Listing
`
`At the time of document entry (noted above):
`eo
`USPTO employees may access SCORE content via eDAN using the Supplemental Content
`tab, or via the SCORE web page.
`External customers may access SCORE content via PAIR using the Supplemental Content
`tab.
`
`e
`
`Form Revision Date: August 26, 2013
`
`0001
`
`0001
`
`MYLAN - EXHIBIT 1021
`
`

`

`PTO/AIA/15 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`
`
`UTILITY
`PATENT APPLICATION
`TRANSMITTAL
`
`Attorney Docket No.
`
`
`
`First Named Inventor
`
`COMISKEY et al.
`
`
`
`Title
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF US
`
`
`
`\_
`
`(Only for new nonprovisional applications under 37 CFR 1.53(b))
`
`Express Mail Label No.
`
`_/
`
`
`
`APPLICATION ELEMENTS
`See MPEP chapter 600 concerning utility patent application contents.
`
`ADDRESS TO:
`
`Commissioner for Patents
`P.O. Box 1450
`
`Alexandria, VA 22313-1450
`
`
`
`
`
`1. [] Fee Transmittal Form
`(PTO/SB/17 or equivalent)
`
`2.
`
`Applicant asserts small entity status.
`See 37 CFR 1.27
`
`3. [] Applicant certifies micro entity status. See 37 CFR 1.29.
`Applicant must attach form PTO/SB/15A or B or equivalent.
`
`[Total Pages 148
`4. [] Specification
`Both the claims and abstract must start on a new page.
`(See MIPEP § 608.01(a) for information on the preferred arrangement)
`5.[] Drawing(s) (35 U.S.C. 113)
`[Total Sheets ©
`]
`
`]
`
`ACCOMPANYING APPLICATION PAPERS
`
`
`
`10. [] Assignment Papers
`(cover sheet & document(s))
`Name of Assignee
`
`
`
`11. [] 37 CFR 3.73(c) Statement
`(when there is an assignee)
`
`[] Power of Attorney
`
`12. [] English Translation Document
`(if applicable)
`
`[Total Pages 8
`6. Inventor's Oath or Declaration
`(including substitute statements under 37 CFR 1.64 and assignments
`serving as an oath or declaration under 37 CFR 1.63(e))
`
`a.
`
`Newly executed (original or copy)
`
`b. [] A copy from a prior application (37 CFR 1.63(d))
`
` * See note below.
`Application Data Sheet
`See 37 CFR 1.76 (PTO/AIA/14 or equivalent)
`
`8.
`
`CD-ROM or CD-R
`in duplicate, large table, or Computer Program (Appendix)
`
`[] Landscape Table on CD
`
`9. Nucleotide and/or Amino Acid Sequence Submission
`(if applicable, items a. — c. are required)
`
`a.
`
`Computer Readable Form (CRF)
`
`b.[] Specification Sequence Listing on:
`
`i. [] CD-ROM or CD-R (2 copies); or
`
`ii.[] Paper
`
`Cc.
`
`Statements verifying identity of above copies
`
`]
`
`13.
`
`Information Disclosure Statement
`(PTO/SB/0S or PTO-1449)
`
`[] Copies of citations attached
`
`14. [] Preliminary Amendment
`
`15. [] Return Receipt Postcard
`(MPEP § 503) (Should be specifically itemized)
`
`16. [] Certified Copy of Priority Document(s)
`(if foreign priority is claimed)
`
`17. [] Nonpublication Request
`Under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35
`or equivalent.
` 18. Other: Certification and Request for Prioritized Examination
`
`Under 37 CFR 1.102(e) [Form PTO/AIA/424]
`
`
`
`
`
`
`
`
`*Note: (1) Benefit claims under 37 CFR 1.78 and foreign priority claims under 1.55 must be included in an Application Data Sheet (ADS).
`(2) For applications filed under 35 U.S.C. 111, the application must contain an ADS specifying the applicant if the applicant is an
`assignee, person to whom the inventor is under an obligation to assign, or person who otherwise shows sufficient proprietary
`interest in the matter. See 37 CFR 1.46(b).
`19. CORRESPONDENCE ADDRESS
`
`
`
`
`
`
`
`The address associated with Customer Number: 58249 OR [] Correspondence address below
`
`
`
`Name
`
`
`
`Address
`
`
`
`
`
`
`
`
`
`
`
`~
`
`
`
` Registration No.
`
` prin/ype) | ANNE E. Fleckenstein
`
`City
`
`Country
`
`[ signature
`
`
`/Anne E. Fleckenstein/
`
`State
`
`Telephone
`
`
`
`
`
`Zip Code
`
`Email
`
`September 4, 2015
`
`Date
`
`
`
`Name
`
`(Attorney/Agent) 62,951
`
`This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO
`to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on
`the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND
`TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PT0O-9199 and select option 2.
`
`0002
`
`
`
`0002
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to
`a patent application or patent.
`Accordingly, pursuant to the
`requirements of the Act, please be advised that: (1) the general authority for the collection of this information is
`35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which
`the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission
`related to a patent application or patent.
`If you do not furnish the requested information, the U.S. Patent and
`Trademark Office may not be able to process and/or examine your submission, which may result in termination
`of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a).
`Records from this system of
`records may be disclosed to the Department of Justice to determine whether disclosure of these
`records is required by the Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting
`evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in
`the course of settlement negotiations.
`a Member of Congress
`A record in this system of records may be disclosed, as a routine use, to
`submitting a request involving an individual, to whom the record pertains, when the individual has
`requested assistance from the Member with respect to the subject matter of the record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency
`having need for the information in order to perform a contract.
`Recipients of information shall be
`required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C.
`552a(m).
`this
`A record related to an International Application filed under the Patent Cooperation Treaty in
`system of records may be disclosed, as a routine use, to the International Bureau of the World
`Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for
`purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act
`(42 U.S.C. 218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that
`agency’s responsibility to recommend improvements in records management practices and programs,
`under authority of 44 U.S.C. 2904 and 2906.
`Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or
`Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public after either
`publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35
`U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine
`use, to the public if the record was filed in an application which became abandoned or in which the
`proceedings were terminated and which application is referenced by either a published application, an
`application open to public inspection or an issued patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local
`law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or
`regulation.
`
`0003
`
`0003
`
`

`

`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C02US
`}
`}
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`
`
`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`
`
`
`
`
`
`
`
`Secrecy Order 37 CFR 5.2
`Hu Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`
`
`Inventor Information:
`
`
`
`Inventor
`Legal Name
`
`1
`
`
`
`
`
`Prefix] Given Name
`Middle Name
`Family Name
`Suffix
`
`
`
`Stephen
`COMISKEY
`
`Residence Information (Select One)
`(¢) US Residency
`()
`Non US Residency
`(0)
`Active US Military Service
`
`
`
`
`
`| US
`Country of Residence i
`State/Province | PA
`City | Doylestown
`
`
`
`
`
` Mailing Address of Inventor:
`
`
`
`Address 1
`
`105 Steeplechase Drive
`
`Address 2
`
`
`
`
`
`City
`
`Doylestown
`
`| State/Province
`
`| PA
`
`
`
`Postal Code
`
`18902
`
`| Country i
`
`us
`
`
`
`2
`Inventor
`Legal Name
`
`
`
`Rong
`
`FENG
`
`
`
`Prefix] Given Name
`Middle Name
`Family Name
`Suffix
`
`
`
`
`Residence Information (Select One)
`(¢) US Residency
`()
`Non US Residency
`() Active US Military Service
`
`
`
`City | Langhorne
`
`State/Province | PA
`
`
`
`
`
`
`Country of Residence i
`
`| US
`
`
`
`
`
`
`
`
` Mailing Address of Inventor:
`
`
`
`Address 1
`
`74 Pine Glen Road
`
`
`Address 2
`
`
`
`City
`
`Langhorne
`
`| State/Province
`
`| PA
`
`
`
`Postal Code
`
`19047
`
`| Country i
`
`| us
`
`
`
`3
`Inventor
`Legal Name
`
`
`
`Prefix| Given Name
`Middle Name
`Family Name
`Suffix
`
`
`
`
`FOSS
`
`
`
`
`
`John
`
`Active US Military Service
`(0)
`Non US Residency
`()
`(¢) US Residency
`Residence Information (Select One)
`00U4
`
`EFS Web 2.2.11
`
`0004
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C02US
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`Title of Invention
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`City | Doylestown
`
`State/Province
`
`| Pa
`
`| Country of Residence i | US
`
`
`
` Mailing Address of Inventor:
`
`
`
`Address 1
`525 Linden Avenue
`
`Address 2
`
`
`
`City
`Postal Code
`
`Doylestown
`
`18901-4435
`
`| State/Province
`| Country i
`Us
`
`| PA
`
`
`
`
`
`4
`Inventor
`Legal Name
`
`
`
`
`
`Prefix] Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`
`Non US Residency
`
`Kunwar
`
`Residence Information (Select One)
`
`(¢) US Residency
`
`()
`
`SHAILUBHAI
`
`
`() Active US Military Service
`
`
`
`
`
`
`
`
`
`
`
`
`
`| US
`Country of Residence i
`State/Province | PA
`City | Audubon
`
`
`
`
`
` Mailing Address of Inventor:
`
`
`
`Address 1
`2707 Bald Eagle Circle
`
`Address 2
`City
`Audubon
`| State/Province
`| PA
`
`
`
`
`
`Postal Code
`
`| 19403
`
`| Country i
`
`| us
`
`
`
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`Add
`
`
`
`Correspondence Information:
`
`
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`[] An Address is being provided for the correspondence Information of this application.
`
`
`
`
`
`Customer Number
`
`58249
`
`
`
`Email Address
`
`zpatdcdocketing@cooley.com
`
`
`
`
`
`
`
`[Remove Email
`|
`Add Email
`|
`
`
`Application Information:
`
`
`
`Title of the Invention
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`Attorney Docket Number| SYPA-009/C02US
`
`Small Entity Status Claimed
`
`
`
`
`
`
`Application Type
`
`Nonprovisional
`
`Subject Matter
`
`Utility
`
`Total Number of Drawing Sheets (if any)
`
`Filing By Reference:
`
`6
`
`
`
`
`
`Suggested Figure for Publication (if any)
`
`
`
`
`
`
`
`EFS Web 2.2.11
`
`0005
`
`
`
`0005
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number | SYPA-009/C02US
`
`
`
`Application Number
`
`
`
`
`
`
`
`Title of Invention
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., “Domestic Benefit/National Stage Information” and “Foreign Priority Information”).
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country i
`
`
`
`
`
`
`
`Publication Information:
`
`
`
`[]
`
`Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`
`
`[J]
`
`Req uest Not to Publish. | hereby request that the attached application not be published under
`35U.S.C.122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`
`
`
`
`
`
`Representative Information:
`
`
`
`all practitioners having a power of attorney in the application. Providing
`Representative information should be provided for
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`
`
`
`
`
`
`
`Please Select One:
`(e
`Customer Number
`(O US Patent Practitioner
`
`Customer Number
`58249
`
`
`
`(O
`
`Limited Recognition (37 CFR 11.9)
`
`
`
`Domestic Benefit/National Stage Information:
`119(e), 120, 121, or 365(c) or indicate National Stage
`This section allows for the applicant to either claim benefit under 35 U.S.C.
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C.
`119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`
`
`Prior Application Status | Pending
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`
`
`Continuation of
`
`14661299
`
`2015-03-18
`
`
`
`Prior Application Status | Pending
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`14661299
`
`Continuation of
`
`13421769
`
`2012-03-15
`
`
`
`
`
`
`Prior Application Status | Expired
`
`EFS Web 2.2.11
`
`0006
`
`0006
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`SYPA-009/C02US
`
`
`
` Application Number
`
`
`
`Title of Invention
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`
`
`13421769
`
`Continuation in part of
`
`PCTUS2011051805
`
`2011-09-15
`
`
`
`Prior Application Status | Expired
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`
`
`PCTUS2011051805
`
`Claims benefit of provisional
`
`61383156
`
`2010-09-15
`
`
`
`Prior Application Status | Expired
`
`Application Number
`
`Continuity Type
`
`
`
` 2010-10-12
`
`
`
` Claims benefit of provisional
`
`
`
`PCTUS2011051805
`Claims benefit of provisional
`Prior Application Status | Expired
`
`Application Number
`
`Continuity Type
`
`
`
`
`
`Prior Application Number |
`
`Filing Date (YYYY-MM-DD)
`
`Prior Application Number |
`
`Filing Date (YYYY-MM-DD)
`
`61387636
`
`2010-09-29
`
`
`
`
`
`PCTUS2011051805
`
`61392186
`
` Additional Foreign Priority Data may be generated within this form by selecting the
`
`
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`Add
`
`
`
`Foreign Priority Information:
`
`
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). When priority is claimed to a foreign application
`
`that is eligible for retrieval under the priority document exchange program (PDX) ithe information will be used by the Office to
`
`automatically attempt retrieval pursuant to 37 CFR 1.55(h){1) and (2). Under the PDX program, applicant bears the ultimate
`
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`
`
`
`
`Application Number
`
`Country i
`
`Access Code (if applicable)
`
` | Remove |
`Filing Date (YYYY-MM-DD)
`
`
`
`
`
`
`
`
`Add button.
`
`Add
`
`
`
`EFS Web 2.2.11
`
`0007
`
`0007
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C02US
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`
`
`
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
` This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AlA.
`
`[]
`
`
`
`
`
`
`
`Authorization to Permit Access:
`
`
`
`Authorization to Permit Access to the Instant Application by the Participating Offices
`
` If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPQO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.
`
`
`
`
`
`
`
`Applicant Information:
`
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`
`
`
`
`
`EFS Web 2.2.11
`
`0008
`
`0008
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C02US
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
`Applicant
`
`1
`
`
`
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`
`
`(OO Assignee
`
`(O
`
`Legal Representative under 35 U.S.C. 117
`
`(O
`
`Joint Inventor
`
`
`(® Person to whom the inventor is obligated to assign.
`
`
`
`
` If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`O
`
`
`Person who shows sufficient proprietary interest
`
`
`
`
`
`Name of the Deceased or Legally Incapacitated Inventor :
`
`
`
`
`
`
`
`
`
`If the Applicant is an Organization check here.
`
`
`
`
`
`Organization Name
`
` Synergy Pharmaceuticals Inc.
`Mailing Address Information:
`
`
`
`
`
`Address 1
`
`420 Lexington Avenue
`
`Address 2
`
`Suite 2012
`
`
`
`
`
`City
`
`New York
`
`State/Province
`
`NY
`
`
`
`
`
`Country il
`
`
`Phone Number
`
`us
`
`Postal Code
`
`10170
`
`Fax Number
`
`Email Address
`
`
`
`
`
`
`
`
`
`
`
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Add
`
`
`
`Assignee Information including Non-Applicant Assignee Information:
`
`
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`
`
`
`
`Assignee
`
`1
`
` Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication . An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`
`
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`Remove
`
`[]
`
`
`
`
`
`
` 0009
`
`EFS Web 2.2.11
`
`0009
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1.76
` Application Number
`
`Attorney Docket Number
`
`SYPA-009/C02US
`
`
`
`
`
`Title of Invention
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
`
`
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`
`
`Address 1
`
`Address 2
`
`
`City
`State/Province
`
`Country i
`Postal Code
`
`
`
`
`
`Phone Number
`
`Email Address
`
`Fax Number
`
`
`
`
`
`
`
` Signature:
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Fv
`
`
`
`
`
`NOTE: This form must be sighed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications
`
`
`
`Signature
`
`|/Anne E. Fleckenstein/
`
`Date (YYYY-MM-DD)|
`
`2015-09-04
`
`
`
`Last Name | Fleckenstein
`
`
`
`
`First Name | Anne E.
`
`
`
`Registration Number | 62951
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`Add
`
`
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.11
`
`0010
`
`0010
`
`

`

`Privacy Act Statement
`
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`a Member of Congress submitting a request involving an
`A record in this system of records may be disclosed, as a routine use, to
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U.S.C. 2804 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant]
`to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State